Physician profile
David N Pickering
NPI 1932412442
$599,057.86
in general payments reported to CMS, 2019-2025
34 companies · $155K in 2025
The $155K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60K · 2020: $44K · 2021: $63K · 2022: $107K · 2023: $69K · 2024: $101K · 2025: $155K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $246K · Travel and Lodging: $48K · Honoraria: $17K · Food and Beverage: $15K · Gift: $119 · Education: $75.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $245,609.28 |
| Travel and Lodging | $47,653.29 |
| Honoraria | $17,230.00 |
| Food and Beverage | $14,503.14 |
| Gift | $118.80 |
| Education | $75.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $225,770.59 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $129,316.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $106,347.30 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42,679.78 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $30,111.01 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $25,687.28 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Mannkind Corporation | $18,564.98 | 2019-2025 | Afrezza, V-Go |
| Tandem Diabetes Care, INC. | $5,483.76 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $3,361.95 | 2019-2023 | |
| Medtronic, INC. | $3,118.39 | 2021-2024 | Minimed 780g, Minimed 770g |
| Valeritas, INC. | $1,462.26 | 2019 | |
| Zealand Pharma US, INC. | $1,276.57 | 2020-2021 | |
| Cequr Corporation | $1,251.51 | 2023-2025 | Cequr Simplicity |
| Abbott Laboratories | $1,012.43 | 2020-2025 | Freestyle Libre 3, Proclaim, Freestyle Insulinx |
| Insulet Corporation | $984.92 | 2020-2025 | Omnipod |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $586.61 | 2019-2023 | Steglatro, Steglujan |
| Bayer Healthcare Pharmaceuticals INC. | $341.30 | 2021-2023 | |
| Dexcom, INC. | $311.18 | 2019-2024 | Dexcom G6 Transmitter |
| Janssen Scientific Affairs, LLC | $209.23 | 2019 | |
| Xeris Pharmaceuticals, INC. | $205.51 | 2021-2024 | Recorlev, Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $204.48 | 2020-2021 | |
| Melinta Therapeutics, LLC | $125.00 | 2024 | Rezzayo |
| Ascensia Diabetes Care US INC. | $120.12 | 2023 | |
| Ironshore Pharmaceuticals INC. | $110.67 | 2023 | Jornay Pm |
| Eusa Pharma (US) LLC | $73.54 | 2022 | |
| Recordati_rare_diseases_inc. | $73.54 | 2022 | |
| Beta Bionics, INC. | $64.32 | 2024 | Ilet Bionic Pancreas |
| Sequel Med Tech, LLC | $47.62 | 2025 | Twiist |
| Abbvie INC. | $38.58 | 2022 | |
| Senseonics, Incorporated | $35.00 | 2020 | |
| Averitas Pharma INC. | $34.91 | 2023-2024 | Qutenza |
| Amarin Pharma, INC. | $22.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.42 | 2022 | |
| Ethicon US, LLC | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pickering listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.